iShares Biotechnology ETF

Should You Invest in the iShares Biotechnology ETF (IBB)?

Launched on February 5, 2001, the iShares Biotechnology ETF (IBB) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.

ETFs That You May Consider Amid a Strengthening Biotech Outlook

Drug innovation, AI and rising M&A activity are boosting biotech optimism. Discover ETFs offering exposure to the sector.

Invesco's RSPH or iShares' IBB: Which Healthcare ETF Is the Better Long-Term Buy?

Invesco S&P 500 Equal Weight Health Care ETF offers a lower expense ratio and a higher dividend yield than iShares Biotechnology ETF. iShares Biotechnology ETF provides concentrated biotech exposure while Invesco S&P 500 Equal Weight Health Care ETF covers the broader healthcare sector.

Biotech stocks are surging. How investors can play the new drug innovation boom

Biotech stocks are rallying as clinical wins, M&A and new drug technologies revive the sector. Here are the ETFs and stocks analysts favor.

Invesco Pharmaceuticals ETF vs. iShares Biotechnology ETF: Which Is the Better Buy?

Here's how pharmaceutical stocks compare to biotech in terms of risk, rewards, and costs.

iShares Biotechnology ETF $IBB Shares Sold by Fairvoy Private Wealth LLC

Moderna Rallies 6% as Money Rotates Into Healthcare; BioNTech and Pfizer Edge Higher

Healthcare is drawing fresh buying as money moves away from the market's popular technology trade, and one messenger RNA (mRNA) name is pulling well ahead of the pack. Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares are up 6% to $239.

Better Buy: Fidelity Health Care ETF (FHLC) or iShares Biotechnology ETF (IBB)?

Fidelity MSCI Health Care Index ETF offers a significantly lower expense ratio of 0.08% compared to 0.44% for the iShares Biotechnology ETF. iShares Biotechnology ETF is more concentrated, with 87% of its portfolio in biotechnology stocks.